Jayesh Desai
0000-0003-4246-9344
Publication & Citation Trends
Publications
0 total
Abstract PS1-10-07: Progression free survival and exploratory endpoints from PALVEN: a phase 1b study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
Cited by 0
Semantic Scholar
BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Cited by 1
Semantic Scholar
Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).
Cited by 0
Semantic Scholar
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
Cited by 18
Semantic Scholar
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Cited by 70
Semantic Scholar
A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study OA
Cited by 0
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(190)
Cancer Genomics and Diagnostics
(94)
Lung Cancer Treatments and Mutations
(78)
Sarcoma Diagnosis and Treatment
(75)
Cancer Immunotherapy and Biomarkers
(72)
Affiliations
American College of Radiology
South Australia Pathology
Roche (Switzerland)
Brigham and Women's Hospital
Novartis (Switzerland)